Handelsavisen
prelaunch
Companies Healthcare BLCO.K
BL
BLCO.K NYSE Diversified Medical Equipment & Supplies

Blco.K

$15,59
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
5,6B USD
P/E
EV / Rev
Div yield
Op margin
2,1 %
ROE
-5,6 %
Net margin
-7,1 %
Debt / equity
0,79
Beta
52w range
Volume
Day range
Prev close
$16,20
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

BLCO.K operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in the healthcare sector.

Business. BLCO.K operates in the Medical Equipment, Supplies & Distribution industry within the broader Healthcare Services & Equipment sector. The company generates revenue primarily through the sale of products. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
HOLD13 analysts
4 buy8 hold1 sell
Avg 12m price target18,25

Analyst recommendations

13 analysts · consensus Hold
Buy4
Hold8
Sell1
12-month price target
18,25
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
13 analysts · indicative
Ownership
Arrowstreet Capital, Limited Partnership
largest disclosed fund holder
Profitability
-5,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BLCO.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BLCO.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    This is the first analysis for Bausch + Lomb Corp (BLCO.K), meaning there is no prior basis for computing material changes in the company's profile. Consequently, the current snapshot serves as the initial baseline for tracking the firm's financial and ownership dynamics. The most notable activity involves a series of new institutional holdings detected as of the end of the first quarter of 2026. Multiple investors initiated positions in the stock, with filings reflecting share acquisitions ranging from small stakes to more significant blocks. For instance, one investor added 1,224,603 shares valued at approximately $19.5 million, while another acquired 845,914 shares worth roughly $13.5 million. Additional notable additions include positions of 453,179 shares valued at $7.2 million, 292,886 shares valued at $4.7 million, and 85,779 shares valued at $1.4 million. A smaller position of 22,274 shares, valued at $0.3 million, was also recorded as of June 30, 2024. These entries indicate a broadening of the shareholder base during this period. Bausch + Lomb currently has 13 top holders and one officer on record, with no analyst coverage or index membership noted in this initial assessment. The influx of new institutional capital suggests growing interest in the company, providing a foundation for future monitoring of ownership concentration and potential market sentiment shifts.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    BLCO.K operates in the Medical Equipment, Supplies & Distribution industry within the broader Healthcare Services & Equipment sector. The company generates revenue primarily through the sale of products. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.79, indicating a moderate level of leverage. The liquidity position is marked by a current ratio of 1.55, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -280 million USD, which may indicate a need for external financing or operational adjustments.

    Profitability metrics show a return on equity of -5.58% and a return on assets of -2.57%, both of which are below the industry median, indicating that the company is underperforming in terms of generating returns for its shareholders and assets. The operating margin is 2.1%, which is also below the industry median, suggesting that the company is not as efficient in converting revenue into operating profit as its peers.

    The company's revenue is concentrated in a single segment, with no disclosed geographic diversification, which may expose the company to higher risk if the segment or region experiences a downturn. The company's growth trajectory is uncertain, with no significant revenue growth reported in the latest financial period.

    The company faces a risk of dilution, although the risk is currently assessed as low. The company's liquidity risk is medium, as indicated by the risk assessment, and the company has a negative net cash position after subtracting total debt. Recent events, such as the company's net loss of 360 million USD, may impact investor sentiment and the company's ability to attract capital.

    This is the first analysis for Bausch + Lomb Corp (BLCO.K), meaning there is no prior basis for computing material changes in the company's profile. Consequently, the current snapshot serves as the initial baseline for tracking the firm's financial and ownership dynamics. The most notable activity involves a series of new institutional holdings detected as of the end of the first quarter of 2026. Multiple investors initiated positions in the stock, with filings reflecting share acquisitions ranging from small stakes to more significant blocks. For instance, one investor added 1,224,603 shares valued at approximately $19.5 million, while another acquired 845,914 shares worth roughly $13.5 million. Additional notable additions include positions of 453,179 shares valued at $7.2 million, 292,886 shares valued at $4.7 million, and 85,779 shares valued at $1.4 million. A smaller position of 22,274 shares, valued at $0.3 million, was also recorded as of June 30, 2024. These entries indicate a broadening of the shareholder base during this period. Bausch + Lomb currently has 13 top holders and one officer on record, with no analyst coverage or index membership noted in this initial assessment. The influx of new institutional capital suggests growing interest in the company, providing a foundation for future monitoring of ownership concentration and potential market sentiment shifts.

    Key takeaways
    • The company has a moderate level of leverage with a debt-to-equity ratio of 0.79.
    • The company's profitability metrics are below the industry median, indicating underperformance.
    • The company's revenue is concentrated in a single segment, which may increase risk.
    • The company's liquidity position is medium, with a current ratio of 1.55.
    • The company has a negative free cash flow, which may require external financing.
    • The company's risk of dilution is currently assessed as low.
    • margin_outlook_rationale: The company's operating margin is below the industry median, indicating potential inefficiencies in converting revenue into profit.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $15,59
    Market cap
    $5.70B
    Enterprise value
    $10.40B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    36.8x
    P / B
    0.9x
    P / Tangible book
    0.9x
    Tangible book
    $6.45B
    Net cash
    -$4.70B
    Current ratio
    1.6
    Debt / equity
    0.8
    ROA
    -2.6%
    ROE
    -5.6%
    Cash conversion
    -79.0%
    CapEx / revenue
    -6.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Ophthalmic Surgical Devices18,0 %
    low · business_description · 2026-07-03
    Contact Lenses
    low · business_description · 2026-07-03
    Lens Care Products
    low · business_description · 2026-07-03
    OTC Eye Drops
    low · business_description · 2026-07-03

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setBLCO 2,0% · rank #13 of 84

    Business relationships

    Business relationships83 disclosed relationships · 3 types · extracted from filings & disclosures
    Customers2
    Subsidiaries80
    EX21:02d370b0d503EX21:02d370b0d503Subsidiarie97%
    EX21:02f32e1ae4e6EX21:02f32e1ae4e6Subsidiarie97%
    EX21:02f85b741f3cEX21:02f85b741f3cSubsidiarie97%
    EX21:0773ecc8d3f3EX21:0773ecc8d3f3Subsidiarie97%
    EX21:077cfb05ef37EX21:077cfb05ef37Subsidiarie97%
    EX21:07d98829bf57EX21:07d98829bf57Subsidiarie97%
    EX21:094776714220EX21:094776714220Subsidiarie97%
    EX21:09b6dd95fd61EX21:09b6dd95fd61Subsidiarie97%
    EX21:0b0d91587ee7EX21:0b0d91587ee7Subsidiarie97%
    EX21:135d2176e09eEX21:135d2176e09eSubsidiarie97%
    EX21:141d42512071EX21:141d42512071Subsidiarie97%
    EX21:173928907ed1EX21:173928907ed1Subsidiarie97%
    EX21:19d28abd96f8EX21:19d28abd96f8Subsidiarie97%
    EX21:1b3552f7ac7cEX21:1b3552f7ac7cSubsidiarie97%
    EX21:1d915f8db9e5EX21:1d915f8db9e5Subsidiarie97%
    EX21:2108ad4f1408EX21:2108ad4f1408Subsidiarie97%
    EX21:26ec07ee294aEX21:26ec07ee294aSubsidiarie97%
    EX21:27d655ec923fEX21:27d655ec923fSubsidiarie97%
    EX21:291fe144f23fEX21:291fe144f23fSubsidiarie97%
    EX21:29a58f090992EX21:29a58f090992Subsidiarie97%
    EX21:30110549a74aEX21:30110549a74aSubsidiarie97%
    EX21:309da2cdff71EX21:309da2cdff71Subsidiarie97%
    EX21:30e16fd03c7eEX21:30e16fd03c7eSubsidiarie97%
    EX21:3107ebe999abEX21:3107ebe999abSubsidiarie97%
    EX21:3c241048120fEX21:3c241048120fSubsidiarie97%
    EX21:3c68f740d176EX21:3c68f740d176Subsidiarie97%
    EX21:3e60012aae9eEX21:3e60012aae9eSubsidiarie97%
    EX21:421f3edf95b5EX21:421f3edf95b5Subsidiarie97%
    EX21:4d6af6ade4ebEX21:4d6af6ade4ebSubsidiarie97%
    EX21:4d908d97224cEX21:4d908d97224cSubsidiarie97%
    EX21:515bd3c88c98EX21:515bd3c88c98Subsidiarie97%
    EX21:519f4ae11243EX21:519f4ae11243Subsidiarie97%
    EX21:5a2aecf78401EX21:5a2aecf78401Subsidiarie97%
    EX21:5a74bd3c831eEX21:5a74bd3c831eSubsidiarie97%
    EX21:5b74f75a4f11EX21:5b74f75a4f11Subsidiarie97%
    EX21:5b905f52dab7EX21:5b905f52dab7Subsidiarie97%
    EX21:6259db147a11EX21:6259db147a11Subsidiarie97%
    EX21:64e54eec6961EX21:64e54eec6961Subsidiarie97%
    EX21:66f12afa53e9EX21:66f12afa53e9Subsidiarie97%
    EX21:6ff05f46ca13EX21:6ff05f46ca13Subsidiarie97%
    EX21:70c9760538aeEX21:70c9760538aeSubsidiarie97%
    EX21:74c9c3007afdEX21:74c9c3007afdSubsidiarie97%
    EX21:74f2ab70931fEX21:74f2ab70931fSubsidiarie97%
    EX21:788d850fde1aEX21:788d850fde1aSubsidiarie97%
    EX21:7af9abb3cea8EX21:7af9abb3cea8Subsidiarie97%
    EX21:7ca8dd88bf3eEX21:7ca8dd88bf3eSubsidiarie97%
    EX21:81f92dea3004EX21:81f92dea3004Subsidiarie97%
    EX21:827c191795dbEX21:827c191795dbSubsidiarie97%
    EX21:8677fcbda33dEX21:8677fcbda33dSubsidiarie97%
    EX21:883b034dabc5EX21:883b034dabc5Subsidiarie97%
    EX21:888981da2a09EX21:888981da2a09Subsidiarie97%
    EX21:903f86014524EX21:903f86014524Subsidiarie97%
    EX21:94a55ca46042EX21:94a55ca46042Subsidiarie97%
    EX21:97d1be80db1fEX21:97d1be80db1fSubsidiarie97%
    EX21:97e07729e823EX21:97e07729e823Subsidiarie97%
    EX21:9e4a117d2096EX21:9e4a117d2096Subsidiarie97%
    EX21:a26f54ce073dEX21:a26f54ce073dSubsidiarie97%
    EX21:a2a376df2050EX21:a2a376df2050Subsidiarie97%
    EX21:a5b58036cc65EX21:a5b58036cc65Subsidiarie97%
    EX21:ac333393c18fEX21:ac333393c18fSubsidiarie97%
    EX21:ac6511eb121fEX21:ac6511eb121fSubsidiarie97%
    EX21:ae9377d8bd12EX21:ae9377d8bd12Subsidiarie97%
    EX21:bc7877a75af0EX21:bc7877a75af0Subsidiarie97%
    EX21:bc81ead2038dEX21:bc81ead2038dSubsidiarie97%
    EX21:bfa5fcd1710eEX21:bfa5fcd1710eSubsidiarie97%
    EX21:c6163a5169d1EX21:c6163a5169d1Subsidiarie97%
    EX21:c871dff21533EX21:c871dff21533Subsidiarie97%
    EX21:d1c89fe1ac23EX21:d1c89fe1ac23Subsidiarie97%
    EX21:d35d54e35df4EX21:d35d54e35df4Subsidiarie97%
    EX21:d42b3913a656EX21:d42b3913a656Subsidiarie97%
    EX21:d529ea1efef5EX21:d529ea1efef5Subsidiarie97%
    EX21:d875718274dcEX21:d875718274dcSubsidiarie97%
    EX21:de71427531f3EX21:de71427531f3Subsidiarie97%
    EX21:e43c3a7c0dd1EX21:e43c3a7c0dd1Subsidiarie97%
    EX21:f186b5091dd1EX21:f186b5091dd1Subsidiarie97%
    EX21:f20e577942c1EX21:f20e577942c1Subsidiarie97%
    EX21:f484ab857a3dEX21:f484ab857a3dSubsidiarie97%
    EX21:f795490ad8edEX21:f795490ad8edSubsidiarie97%
    EX21:fb17afe1088dEX21:fb17afe1088dSubsidiarie97%
    EX21:fea81731eaefEX21:fea81731eaefSubsidiarie97%

    Supply chain

    Vendors → BLCO ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSBLCOBLCOBlco.K83 entitiesBAUSCH HEALTH COMPANIEPharmaceuticalsCACardinal Health IncDiversified PharmaceuticUSMckesson CorpDiversified PharmaceuticUS
    3 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-07-04

    Peer comparison

    Peer comparison8 peers · vs BLCO · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    +18,2 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    +15,4 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    +19,2 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    +12,6 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    +8,6 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    -9,8 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +36,5 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,78
    Predicted surprise
    -0,00
    Beat probability
    45 %
    Analysts
    13
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,80
    Revenueno estimateno estimate5,5B USD
    Operating incomeno estimateno estimate732,5M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution12 analysts
    Strong buy1
    Buy4
    Hold6
    Sell1
    Strong sell0
    12-month price target$18,36 · Median $18,00
    Low $16,00High $21,00
    Operating income · consensus732,5M USD
    EPS surprise
    −36,6 %
    reported vs consensus · miss
    Revenue surprise
    −6,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$16,00
    Mean$18,25
    Median$18,00
    High$21,00
    Spot$15,59
    +17.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin2,1 %Above median
    Net Margin-7,1 %Below median
    ROE-5,6 %Below median
    Capex / Rev-6,8 %Bottom quartile
    D/E0,79Bottom quartile
    Cash Conv-0,79Bottom quartile

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • BLCO.K Market data — financials · 2026-05-27
    • Bausch + Lomb Corp Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Top holders

    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,01 %$16M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$7M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$13M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$5M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$2M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$2M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

    Leadership

    • Brent L. SaundersChairman of the Board, Chief Executive Officer

    Insider activity

    Net buying4 buys · 0 sellsnet $650K16 insiders · last 365d
    • Bonnefoy LucPresident, Surgical · Common Shares, No Par ValueOther 1 008 @ $15,08$15K · 2026-06-12
    • VON ESCHENBACH ANDREW C.Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • Ross Thomas W. Sr.Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • ROBERTSON RUSSEL CDirector · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • Paulson JohnDirector · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • Ling KarenDirector · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • KAVANAGH SARAH BDirector · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • COLLIS STEVEN HDirector · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • Bernier Nathalie D.Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • Alfonso EduardoDirector · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
    • SAUNDERS BRENT LDirector, Chairman of the Board and CEO · Common Shares, No Par ValueOther 2 886 @ $15,92$46K · 2026-05-22
    • Munsch FrederickSVP, Controller and CAO · Common Shares, No Par ValueOther 8 673 @ $16,00$139K · 2026-05-05
    • Eldessouky SamEVP and CFO · Common Shares, No Par ValueOther 63 938 @ $16,00$1,0M · 2026-05-05
    • Hashad YehiaEVP of R&D and CMO · Common Shares, No Par ValueOther 13 664 @ $16,00$219K · 2026-05-05
    • Bonnefoy LucPresident, Surgical · Common Shares, No Par ValueOther 11 970 @ $16,00$192K · 2026-05-05
    • COLLIS STEVEN HDirector · Common Shares, No Par ValueOther 1 415 @ $15,90$22K · 2026-04-30
    • ROBERTSON RUSSEL CDirector · Common Shares, No Par ValueOther 1 611 @ $15,90$26K · 2026-04-30
    • Paulson JohnDirector · Common Shares, No Par ValueOther 1 375 @ $15,90$22K · 2026-04-30
    • Alfonso EduardoDirector · Common Shares, No Par ValueOther 1 375 @ $15,90$22K · 2026-04-30
    • Stewart Andrew J.President, GPIC · Common Shares, No Par ValueOther 4 216 @ $15,82$67K · 2026-04-24
    • Bailey A Robert DEVP & Chief Legal Officer · Common Shares, No Par ValueOther 15 806 @ $15,82$250K · 2026-04-24
    • SAUNDERS BRENT LDirector, CEO and Chairman of the Board · Common Shares, No Par ValueOther 14 700 · 2026-03-06
    • Bailey A Robert DEVP & Chief Legal Officer · Common Shares, No Par ValueBought 14 600 @ $17,15$250K · 2026-03-06
    • Bailey A Robert DEVP & Chief Legal Officer · Common Shares, No Par ValueOther 14 600 · 2026-03-06
    • Eldessouky SamEVP and CFO · Common Shares, No Par ValueBought 4 000 @ $17,13$69K · 2026-03-06

    Short positioning

    3.8Mshares short-4.6% vs prior
    10.26days to cover
    50.9%short of daily vol
    2.1Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BLCO.KCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,00M&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    BLCOCAH.OMCK.OBHC.TOEX21:02dEX21:02fEX21:02fEX21:077EX21:077EX21:07dEX21:094Diversified Me
    This companySectorCustomersPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 8.3%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 4.1%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -0.4%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 6.5%Derived (calculated)
    • Net margin (FY 2025-12-31): -7.1%Derived (calculated)
    • Return on equity (FY 2025-12-31): -5.6%Derived (calculated)
    • Return on assets (FY 2025-12-31): -2.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.55xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.16xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 19.9%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 25.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -13.3%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -13.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -13.6%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 5.5%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -30.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 22.0%Derived (calculated)
    • Net income (annual): USD -360MSEC XBRL filing
    • Long-term debt (annual): USD 5.05BSEC XBRL filing
    • Total assets (annual): USD 14.02BSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Capex (annual): USD 349MSEC XBRL filing
    • Pre-tax income (annual): USD -317MSEC XBRL filing
    • Current liabilities (annual): USD 1.92BSEC XBRL filing
    Showing 24 of 52 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-30 04:36 UTCFILINGMaterial 8-K
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER11 institutional position changes flagged
    2026-06-12 00:00 UTCINSIDER1 insider transaction — 2026-06
    2026-06-12 00:00 UTCINSIDER1 insider transaction — 2026-06
    2026-06-12INSIDERBonnefoy Luc transacted 1.0k sh Common Shares, No Par Value — President, Surgical ~$15k
    2026-05-26 00:00 UTCINSIDER14 insider transactions — 2026-05 · net buy $632k
    2026-05-26 00:00 UTCINSIDER14 insider transactions — 2026-05 · net buy $632k
    2026-05-26INSIDERVON ESCHENBACH ANDREW C. transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERRoss Thomas W. Sr. transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERROBERTSON RUSSEL C transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERPaulson John transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERLing Karen transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERKAVANAGH SARAH B transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERCOLLIS STEVEN H transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERBernier Nathalie D. transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-26INSIDERAlfonso Eduardo transacted 15.8k sh Common Shares, No Par Value — Director ~$250k
    2026-05-22INSIDERSAUNDERS BRENT L transacted 2.9k sh Common Shares, No Par Value — Director, Chairman of the Board and CEO ~$46k
    2026-05-20FILING8-K filing →
    2026-05-05INSIDERMunsch Frederick transacted 8.7k sh Common Shares, No Par Value — SVP, Controller and CAO ~$139k
    2026-05-05INSIDEREldessouky Sam transacted 63.9k sh Common Shares, No Par Value — EVP and CFO ~$1.02M
    2026-05-05INSIDERHashad Yehia transacted 13.7k sh Common Shares, No Par Value — EVP of R&D and CMO ~$219k
    2026-05-05INSIDERBonnefoy Luc transacted 12.0k sh Common Shares, No Par Value — President, Surgical ~$192k
    2026-04-30 00:00 UTCINSIDER6 insider transactions — 2026-04 · net sell $225k
    2026-04-30 00:00 UTCINSIDER6 insider transactions — 2026-04 · net sell $225k
    2026-04-30INSIDERCOLLIS STEVEN H transacted 1.4k sh Common Shares, No Par Value — Director ~$22k
    2026-04-30INSIDERROBERTSON RUSSEL C transacted 1.6k sh Common Shares, No Par Value — Director ~$26k
    2026-04-30INSIDERPaulson John transacted 1.4k sh Common Shares, No Par Value — Director ~$22k
    2026-04-30INSIDERAlfonso Eduardo transacted 1.4k sh Common Shares, No Par Value — Director ~$22k
    2026-04-29FILING10-Q filing →
    Showing the 40 most recent of 58 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage